Inside Innovation

AGC Biologics announced a strategic partnership with Pyramid Pharma Services to provide integrated U.S.-based drug substance manufacturing and sterile fill-finish services for biopharmaceutical developers. The

Bellevue-based clinical-stage biotech company Zymeworks is acquiring Theravance Biopharma in a $929 million deal, expanding beyond oncology into respiratory disease. The acquisition adds Yupelri, an

The University of Washington has ranked third within public universities and twelfth globally by U.S. News & World Report in its 2026-2027 Best Global Universities,

This year’s BioCentury Grand Rounds brought together researchers, biotech leaders, investors, and Nobel laureates in Seattle to explore how big data can accelerate medical breakthroughs.

Seattle-based Vedana Therapeutics emerged from stealth with $46 million in Series A financing to develop next-generation therapies for migraine prevention. The company is advancing long-acting

Adaptive Biotechnologies announced plans to pursue a separation of its Minimal Residual Disease and Immune Medicine businesses to support the growth and strategic focus of

Seattle Children’s has been awarded a grant of up to $17.25 million from Aligning Research to Impact Autism (ARIA) to join the international IMPACT Network

The University of Washington School of Medicine has received a $25 million gift from the Franke family to create the Franke Medical School Scholars Program

Bristol Myers Squibb reported phase 3 results showing that its bispecific antibody-drug conjugate izalontamab brengitecan significantly improved survival outcomes for previously treated triple-negative breast cancer

Philips plans to put its longtime Bothell campus up for sale as part of a long-term real estate strategy while maintaining its healthcare operations and

The Allen Institute has launched the Brain Health Accelerator, a new $400 million initiative aimed at developing gene therapies for neurodegenerative diseases including Alzheimer’s, Parkinson’s,

GEN’s annual ranking of the top U.S. biopharma clusters highlights the regions leading the nation in life sciences competitiveness, with Seattle ranked No. 10 overall